Meet us next:   ELRIG UK 2025 – 20 March  ●  IBD Innovate 2025 – 9-10 April  ●  NIH Spring Vendor Exhibit 2025 – 24 April  ●  AACR Annual Meeting 2025 – 27-30 April  ●  ISCT Conference 2025 – 7-9 May  ●  more on our events calendar

Recombinant human/bovine/porcine NRG-1 protein

QK045

Brand: Qkine

Human NRG-1 protein (neuregulin 1) is frequently used in the maintenance of human pluripotent stem cells.  In addition to its widespread use in stem cell culture media, NRG-1 (also known as Heregulin-β1 , HRG-1) has essential roles in vivo including in nervous system, cardiac, and mammary gland development; cancer biology and neurological disorders.

7.5 kDa highly pure, bioactive domain of human NRG-1, comprised of the β isoform of the EGF-like domain of NRG-1 (HRG1-B1). This NRG-1 protein monomer is animal origin-free (AOF) and carrier-protein free (CF).

Qkine 3-for-2 product campaign

Currency: 

Product name Catalog number Pack size Price Price (USD) Price (GBP) Price (EUR)
Recombinant human/bovine/porcine NRG-1 protein, 50 µg QK045-0050 50 µg (select above) $ 185.00 £ 140.00 € 164.00
Recombinant human/bovine/porcine NRG-1 protein, 100 µg QK045-0100 100 µg (select above) $ 280.00 £ 210.00 € 246.00
Recombinant human/bovine/porcine NRG-1 protein, 500 µg QK045-0500 500 µg (select above) $ 725.00 £ 540.00 € 631.00
Recombinant human/bovine/porcine NRG-1 protein, 1000 µg QK045-1000 1000 µg (select above) $ 1,050.00 £ 800.00 € 935.00

Note: prices shown do not include shipping and handling charges.

Qkine company name and logo are the property of Qkine Ltd. UK.

Alternative protein names
Neuregulin1 (NRG1-β1), Neu differentiation factor (rat), Heregulin, HRG, HRG1-β1, Breast cancer cell differentiation factor p45, ARIA (Acetylcholine, Receptor Inducing Activity), glial growth factor
Species reactivity

human

species similarity:
mouse – 98%
rat – 83%
porcine – 100%
bovine – 100%

Frequently used together with:

Summary

  • High purity human NRG-1 protein (Uniprot: Q02297)
  • >98%, by SDS-PAGE quantitative densitometry
  • 7.5 kDa
  • Expressed in E. coli.
  • Animal origin-free (AOF) and carrier protein-free.
  • Manufactured in Qkine's Cambridge, UK laboratories
  • Lyophilized from acetonitrile, TFA
  • Resuspend in water at >100 µg/ml, prepare single use aliquots, add carrier protein if desired and store frozen at -20°C or -80°C
Handling and Storage FAQ

Featured applications

  • Maintenance of pluripotency in human iPSC

Bioactivity

Human LIF Qk036 protein bioactivity lot #14293

NRG-1 activity is determined using the Promega serum response element luciferase reporter assay (*) in transfected MCF-7 cells. Cells are treated in triplicate with a serial dilution of NRG-1 for 4 hours. Firefly luciferase activity is measured and normalized to the control Renilla luciferase activity. EC50 = 37.9 pM (0.28 ng/mL). Data from Qk045 lot #104317. *Promega pGL4.33[luc2P/SRE/Hygro] #E1340

Purity

Human LIF Qk036 protein purity SDS-PAGE lot #14293

NRG-1 migrates as a single band at 7.5 kDa in non-reducing (NR) conditions and upon reduction (R).  No contaminating protein bands are visible. Purified recombinant protein (3 µg) was resolved using 18% w/v SDS-PAGE in reduced (+β-mercaptothanol, R) and non-reduced (NR) conditions and stained with Coomassie Brilliant Blue R250.  Data from Qk045 batch #104317.

Further quality assays

  • Mass spectrometry: single species with expected mass
  • Analytical reversed-phase: single sharp peak
  • Endotoxin: <0.005 EU/μg protein (below level of detection)
  • Recovery from stock vial >95%

Protein background

Neuregulin 1 (NRG-1) is a member of the neuregulin family (along with NRG 2-4). Each member of this family is encoded by an individual gene.  Alternative splicing and different promoter utilisation results in a large number of isoforms for each member of the protein family – for example, NRG-1, the best studied member, generates six types of protein (I–VI) and at least 31 isoforms [1]. These isoforms have different tissue distribution, potency, receptor specificity and biological functions [2].

All NRG-1 isoforms contain the bioactive EGF-like domain, this EGF-like domain has two isoforms: alpha and beta. These differ in their receptor affinity; both the alpha and beta isoforms are ligands for the receptors ErbB3 (HER3) and ErbB4 (HER4), however the NRG-1 beta isoform has a higher affinity for the ErbB4 receptor than the alpha isoform [3]. This protein (Qk045) consists of the β isoform of the EGF domain of NRG-1 protein.

NRG-1 has an essential role in cardiac and neuronal development, and is implicated in disorders such as schizophrenia [4], and numerous cancers, for example breast cancer where NRG-1 promotes the proliferation and migration of breast cancer cells [5]. In cell culture, NRG-1 is frequently used in maintenance media for human pluripotent stem cells and other cells.

Background references

  1. Mei, Lin, and Wen-Cheng Xiong. ‘Neuregulin 1 in Neural Development, Synaptic Plasticity and Schizophrenia’. Nature Reviews Neuroscience, vol. 9, no. 6, June 2008, pp. 437–52. doi.org/10.1038/nrn2392.
  2. Breuleux, M. ‘Role of Heregulin in Human Cancer’. Cellular and Molecular Life Sciences, vol. 64, no. 18, Sept. 2007, pp. 2358–77. doi.org/10.1007/s00018-007-7120-0.
  3. Hobbs, Stuart S., et al. ‘Neuregulin Isoforms Exhibit Distinct Patterns of ErbB Family Receptor Activation’. Oncogene, vol. 21, no. 55, Dec. 2002, pp. 8442–52. doi.org/10.1038/sj.onc.1205960.
  4. Shi, Liang, and Clare M. Bergson. ‘Neuregulin 1: An Intriguing Therapeutic Target for Neurodevelopmental Disorders’. Translational Psychiatry, vol. 10, no. 1, June 2020, pp. 1–11. doi.org/10.1038/s41398-020-00868-5.
  5. Berdiel-Acer, Mireia, et al. ‘Stromal NRG1 in Luminal Breast Cancer Defines Pro-Fibrotic and Migratory Cancer-Associated Fibroblasts’. Oncogene, vol. 40, no. 15, Apr. 2021, pp. 2651–66. doi.org/10.1038/s41388-021-01719-3.

Publications using recombinant human NRG-1 protein (Qk045)

Refined home-brew media for cost-effective, weekend-free hiPSC culture and genetic engineering.
In Open Research Europe 2024 by Truszkowski, L., Bottini, S., Bianchi, S. et al.
View publication